Lingor, Paul
Caldi Gomes L, Hänzelmann S, Hausmann F, Khatri R, Oller S, Parvaz M, Tzeplaeff L, Pasetto L, Gebelin M, Ebbing M, Holzapfel C, Columbro SF, Scozzari S, Knöferle J, Cordts I, Demleitner AF, Deschauer M, Dufke C, Sturm M, Zhou Q, Zelina P, Sudria-Lopez E, Haack TB, Streb S, Kuzma-Kozakiewicz M, Edbauer D, Pasterkamp RJ, Laczko E, Rehrauer H, Schlapbach R, Carapito C, Bonetto V, Bonn S, Lingor P. Multiomic ALS signatures highlight subclusters and sex differences suggesting the MAPK pathway as therapeutic target. Nat Commun. 2024 Jun 7;15(1):4893. doi: 10.1038/s41467-024-49196-y. PMID: 38849340; PMCID: PMC11161513.
- Carmona A, Carboni E, Gomes LC, Roudeau S, Maass F, Lenz C, Ortega R, Lingor P. Metal dyshomeostasis in the substantia nigra of patients with Parkinson's disease or multiple sclerosis. J Neurochem. 2024 Jan 5. doi: 10.1111/jnc.16040. Epub ahead of print. PMID: 38178798.
- Danzer B, Jukic M, Dunkel A, Andersen G, Lieder B, Schaudy E, Stadlmayr S, Lietard J, Michel T, Krautwurst D, Haller B, Knolle P, Somoza M, Lingor P, Somoza V. Impaired metal perception and regulation of associated human foliate papillae tongue transcriptome in long-COVID-19. Sci Rep. 2024 Jul 4;14(1):15408. doi: 10.1038/s41598-024-66079-w. PMID: 38965271; PMCID: PMC11224223.
- Hopfner F, Höglinger G; German Parkinson’s Guidelines Group [i.a. Levin J, Lingor P]; Trenkwalder C. Definition and diagnosis of Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology. J Neurol. 2024 Sep 19. doi: 10.1007/s00415-024-12687-5. Epub ahead of print. PMID: 39297986.
- Höglinger G; German Parkinson’s Guidelines Committee [i.a. Levin J, Lingor P]; Trenkwalder C. Diagnosis and treatment of Parkinson´s disease (guideline of the German Society for Neurology). Neurol Res Pract. 2024 Jun 6;6(1):30. doi: 10.1186/s42466-024-00325-4. PMID: 38845028; PMCID: PMC11157782.
- Höllerhage M, Becktepe J, Classen J, Deuschl G, Ebersbach G, Hopfner F, Lingor P, Löhle M, Maaß S, Pötter-Nerger M, Odin P, Woitalla D; German Parkinson’s Guidelines Group [i.a. Levin J]; Trenkwalder C, Höglinger GU. Pharmacotherapy of motor symptoms in early and mid-stage Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology. J Neurol. 2024 Aug 29. doi: 10.1007/s00415-024-12632-6. Epub ahead of print. PMID: 39207521.
- Koch JC, Leha A, Bidner H, Cordts I, Dorst J, Günther R, Zeller D, Braun N, Metelmann M, Corcia P, De La Cruz E, Weydt P, Meyer T, Großkreutz J, Soriani MH, Attarian S, Weishaupt JH, Weyen U, Kuttler J, Zurek G, Rogers ML, Feneberg E, Deschauer M, Neuwirth C, Wuu J, Ludolph AC, Schmidt J, Remane Y, Camu W, Friede T, Benatar M, Weber M, Lingor P; ROCK-ALS Study group. Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024 Nov;23(11):1133-1146. doi: 10.1016/S1474-4422(24)00373-9. PMID: 39424560.
- Tatenhorst L, Maass F, Paul H, Dambeck V, Bähr M, Dono R, Lingor P. Glypican-4 serum levels are associated with cognitive dysfunction and vascular risk factors in Parkinson's disease. Sci Rep. 2024 Feb 29;14(1):5005. doi: 10.1038/s41598-024-54800-8. PMID: 38424123; PMCID: PMC10904781.
Wolff AW, Bidner H, Remane Y, Zimmer J, Aarsland D, Rascol O, Wyse RK, Hapfelmeier A, Lingor P. Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson's disease (ROCK-PD). Front Aging Neurosci. 2024 Feb 14;16:1308577. doi: 10.3389/fnagi.2024.1308577. PMID: 38419648; PMCID: PMC10899319.
Wolff A, Demleitner AF, Feneberg E, Lingor P. Den Rauch riechen, bevor man das Feuer sieht – die oligosymptomatische Prodromalphase neurodegenerativer Erkrankungen [Smell the smoke before one sees the fire-The oligosymptomatic prodromal phase of neurodegenerative diseases]. Nervenarzt. 2024 Apr 17. German. doi: 10.1007/s00115-024-01654-0. Epub ahead of print. PMID: 38630299.
Wolff AW, Peine J, Höfler J, Zurek G, Hemker C, Lingor P. SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants. CNS Drugs. 2024 Feb 28. doi: 10.1007/s40263-024-01070-7. Epub ahead of print. PMID: 38416402.
- Cordts I, Wachinger A, Scialo C, Lingor P, Polymenidou M, Buratti E, Feneberg E (2023). TDP-43 Proteinopathy Specific Biomarker Development. Cells. 2023 Feb 12;12(4):597. doi: 10.3390/cells12040597. PMID: 36831264; PMCID: PMC9954136.
- Heinrich F, Cordts I, Günther R, Stolte B, Zeller D, Schröter C, Weyen U, Regensburger M, Wolf J, Schneider I, Hermann A, Metelmann M, Kohl Z, Linker RA, Koch JC, Radelfahr F, Schönfelder E, Gardt P, Mohajer-Peseschkian T, Osmanovic A, Klopstock T, Dorst J, Ludolph AC, Schöffski O, Boentert M, Hagenacker T, Deschauer M, Lingor P, Petri S, Schreiber-Katz O (2023). Economic evaluation of Motor Neuron Diseases: a nationwide cross-sectional analysis in Germany. J Neurol. 2023 Jun 25. doi: 10.1007/s00415-023-11811-1. Epub ahead of print. PMID: 37356024.
- Luib E, Demleitner AF, Cordts I, Westenberg E, Rau P, Pürner D, Haller B, Lingor P. Reduced tear fluid production in neurological diseases: a cohort study in 708 patients. J Neurol. 2023 Dec 8. doi: 10.1007/s00415-023-12104-3. Epub ahead of print. PMID: 38063868.
- Warth Perez Arias CC, Silbern I, Caldi Gomes L, Wartmann H, Dambeck V, Fanz J, Neuenroth L, Bähr M, Outeiro TF, Bonn S, Stadelmann-Nessler C, Rizzoli SO, Lenz C, Urlaub H, Lingor P (2023). Proteomic analysis of the human hippocampus identifies neuronal pentraxin 1 (NPTX1) as synapto-axonal target in late-stage Parkinson's disease. J Neurochem. 2023 Jul 28. doi: 10.1111/jnc.15924. Epub ahead of print. PMID: 37515330.
- Wolff A, Schumacher NU, Pürner D, Machetanz G, Demleitner AF, Feneberg E, Hagemeier M, Lingor P (2023). Parkinson's disease therapy: what lies ahead? J Neural Transm (Vienna). 2023 May 5. doi: 10.1007/s00702-023-02641-6. Epub ahead of print. PMID: 37147404.
- Wolff AW, Haller B, Demleitner AF, Pürner D, Niederschweiberer J, Cordts I, Westenberg E, Lingor P (2023) Long-Lasting Impact of the COVID-19 Pandemic on Patients with Parkinson's Disease and Their Relatives. Mov Disord Clin Pract. 2023 Apr 12;10(5):819-823. doi: 10.1002/mdc3.13727. PMID: 37205245; PMCID: PMC10187008.
- Zhang S, Dauer K, Strohäker T, Tatenhorst L, Caldi Gomes L, Mayer S, Jung BC, Kim WS, Lee SJ, Becker S, Liesche-Starnecker F, Zweckstetter M, Lingor P (2023). Alpha-synuclein fibrils amplified from multiple system atrophy and Parkinson's disease patient brain spread after intracerebral injection into mouse brain. Brain Pathol. 2023 Jul 24. doi: 10.1111/bpa.13196. Epub ahead of print. PMID: 37485772.
- Cordts I, Önder D, Traschütz A, Kobeleva X, Karin I, Minnerop M, Koertvelyessy P, Biskup S, Forchhammer S, Binder J, Tzschach A, Meiss F, Schmidt A, Kreiß M, Cremer K, Mensah MA, Park J, Rautenberg M, Deininger N, Sturm M, Lingor P, Klopstock T, Weiler M, Marxreiter F, Synofzik M, Posch C, Sirokay J, Klockgether T, Haack TB, Deschauer M (2022). Adult-Onset Neurodegeneration in Nucleotide Excision Repair Disorders (NERDND ): Time to Move Beyond the Skin. Mov Disord. 2022 Jun 14. doi: 10.1002/mds.29071. Epub ahead of print. PMID: 35699229.
- Demleitner AF, Wolff AW, Erber J, Gebhardt F, Westenberg E, Winkler AS, Kolbe-Busch S, Chaberny IF, Lingor P. Best practice approaches to outpatient management of people living with Parkinson's disease during the COVID-19 pandemic. J Neural Transm (Vienna). 2022 Nov;129(11):1377-1385. doi: 10.1007/s00702-022-02484-7. Epub 2022 Mar 4. PMID: 35244753; PMCID: PMC8895054.
- Lingor P, Demleitner AF, Wolff AW, Feneberg E. SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't. J Neural Transm (Vienna). 2022 Sep;129(9):1155-1167. doi: 10.1007/s00702-022-02500-w. Epub 2022 Apr 17. PMID: 35434769; PMCID: PMC9013492.
- Niederschweiberer J, Schumacher NU, Kumpfmüller D, Lingg C, Graf S, Ikenberg B, Mühlau M, Lingor P, Hemmer B, Knier (2022). Das Anti-IgLON5-Syndrom in der klinischen Neurologie – zwei Fallberichte. Nervenarzt. 2022 Jun 15. German. doi: 10.1007/s00115-022-01344-9. Epub ahead of print. PMID: 35704066.